# Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Source: https://onco.cc/trials/nct07165886/  
OnCo record `nct07165886` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Everolimus in pancreatic ductal adenocarcinoma, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.

## Summary

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors is a phase 2/3 interventional study registered as NCT07165886 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 298 participants planned, started 2025-08-29 and due to reach its primary completion in 2028-08-29. Interventions recorded: Sirolimus for injection (albumin bound), Octreotide long-acting injection and Everolimus.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07165886
- Phase: 2/3
- Setting: Phase II/III Study to Evaluate the Safety and Efficacy of Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrolled: 298

## Sources

- ClinicalTrials.gov NCT07165886: https://clinicaltrials.gov/study/NCT07165886

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Everolimus](https://onco.cc/drugs/everolimus/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct07165886.json